SK124897A3 - Recombinant viruses expressing lecithin-cholesterol acyltransferase, and uses thereof in gene therapy - Google Patents

Recombinant viruses expressing lecithin-cholesterol acyltransferase, and uses thereof in gene therapy Download PDF

Info

Publication number
SK124897A3
SK124897A3 SK1248-97A SK124897A SK124897A3 SK 124897 A3 SK124897 A3 SK 124897A3 SK 124897 A SK124897 A SK 124897A SK 124897 A3 SK124897 A3 SK 124897A3
Authority
SK
Slovakia
Prior art keywords
virus
lcat
cholesterol
adenovirus
virus according
Prior art date
Application number
SK1248-97A
Other languages
English (en)
Slovak (sk)
Inventor
Patrice Denefle
Nicolas Duverger
Martine Latta-Mahieu
Sandrine Seguret
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of SK124897A3 publication Critical patent/SK124897A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
SK1248-97A 1995-03-14 1996-03-12 Recombinant viruses expressing lecithin-cholesterol acyltransferase, and uses thereof in gene therapy SK124897A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9502943A FR2731710B1 (fr) 1995-03-14 1995-03-14 Virus recombinants exprimant la lecithine cholesterol acyltransferase et utilisations en therapie genique
PCT/FR1996/000381 WO1996028553A1 (fr) 1995-03-14 1996-03-12 Virus recombinants exprimant la lecithine cholesterol acyltransferase et utilisation en therapie genique

Publications (1)

Publication Number Publication Date
SK124897A3 true SK124897A3 (en) 1998-02-04

Family

ID=9477007

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1248-97A SK124897A3 (en) 1995-03-14 1996-03-12 Recombinant viruses expressing lecithin-cholesterol acyltransferase, and uses thereof in gene therapy

Country Status (15)

Country Link
US (1) US20010014319A1 (ko)
EP (1) EP0815239A1 (ko)
JP (1) JPH11501518A (ko)
KR (1) KR19980703008A (ko)
AU (1) AU711381B2 (ko)
BR (1) BR9607757A (ko)
CA (1) CA2214010A1 (ko)
CZ (1) CZ286897A3 (ko)
FR (1) FR2731710B1 (ko)
HU (1) HUP9801214A3 (ko)
IL (1) IL117466A0 (ko)
NO (1) NO974179D0 (ko)
SK (1) SK124897A3 (ko)
WO (1) WO1996028553A1 (ko)
ZA (1) ZA961998B (ko)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2283007T3 (es) 1995-11-09 2007-10-16 The Government Of The Usa As Represented By The Secretary Of Department Of Health And Human Services Utilizacion de la lecitina colesterol aciltransferasa (lcat) en el tratamiento de la aterosclerosis.
FR2755975B1 (fr) * 1996-11-15 1999-05-07 Rhone Poulenc Rorer Sa Virus recombinants bicistroniques utiles pour le traitement de pathologies liees aux dyslipoproteinemies
CA2284832A1 (en) * 1997-04-11 1998-10-22 Takeda Chemical Industries, Ltd. Proteins having lecithin-cholesterol acyltransferase-like activity, their production and use
CN100362364C (zh) * 2001-06-19 2008-01-16 派科斯弗洛霍尔丁公司 定位,通讯及跟踪系统
CN1671836B (zh) 2002-06-18 2012-02-08 卫材R&D管理有限公司 用于基因治疗的原代培养脂肪细胞
EP2037740A4 (en) * 2006-06-07 2011-12-28 Reddys Lab Ltd Dr COMPOSITIONS AND METHODS FOR IMPROVING THE REVERSE CHOLESTER INTRANSPORT
EP2037928B1 (en) 2006-06-26 2012-01-11 Amgen Inc. Methods for treating atherosclerosis
JPWO2008108344A1 (ja) * 2007-03-02 2010-06-17 セルジェンテック株式会社 Ｌｃａｔ欠損症の遺伝子治療用細胞並びに遺伝子治療用細胞組成物
MX2019003160A (es) 2016-09-20 2019-05-27 Boehringer Ingelheim Vetmedica Gmbh Nuevos promotores.
MX2019003116A (es) 2016-09-20 2019-08-29 Boehringer Ingelheim Vetmedica Gmbh Nueva vacuna contra la gripe porcina.
MX2019003158A (es) 2016-09-20 2019-05-27 Boehringer Ingelheim Vetmedica Gmbh Vectores de adenovirus canino.
UY37406A (es) 2016-09-20 2018-03-23 Boehringer Ingelheim Vetmedica Gmbh Nuevo sitio de inserción orf70 de ehv

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8424757D0 (en) * 1984-10-01 1984-11-07 Pasteur Institut Retroviral vector
US5049488A (en) * 1985-11-08 1991-09-17 Genentech, Inc. Method and nucleic acid for the preparation of lecithin:cholesterol acyltransferase
US5252479A (en) * 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2705361B1 (fr) * 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
HU216871B (hu) * 1993-07-13 1999-09-28 Rhone-Poulenc Rorer S.A. Defektív adenovírusvektorok és génterápiai alkalmazásuk

Also Published As

Publication number Publication date
IL117466A0 (en) 1996-07-23
ZA961998B (en) 1996-09-26
AU5008296A (en) 1996-10-02
NO974179L (no) 1997-09-10
AU711381B2 (en) 1999-10-14
JPH11501518A (ja) 1999-02-09
KR19980703008A (ko) 1998-09-05
EP0815239A1 (fr) 1998-01-07
WO1996028553A1 (fr) 1996-09-19
MX9706569A (es) 1997-11-29
FR2731710B1 (fr) 1997-04-30
BR9607757A (pt) 1999-01-26
US20010014319A1 (en) 2001-08-16
NO974179D0 (no) 1997-09-10
HUP9801214A3 (en) 2000-08-28
CA2214010A1 (fr) 1996-09-19
FR2731710A1 (fr) 1996-09-20
CZ286897A3 (en) 1997-12-17
HUP9801214A2 (hu) 1998-08-28

Similar Documents

Publication Publication Date Title
USRE38556E1 (en) Recombinant adeno viruses comprising an inserted gene encoding apolipoprotein and their use in gene therapy for dyslipoproteinemias
US6174527B1 (en) Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism
SK124897A3 (en) Recombinant viruses expressing lecithin-cholesterol acyltransferase, and uses thereof in gene therapy
Van Craeyveld et al. Gene therapy to improve high-density lipoprotein metabolism and function
US20130210898A1 (en) Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to same
US20130164262A1 (en) Recombinant Viruses and their Use for Treatment of Atherosclerosis and Othe Forms of Coronary Artery Disease and Method, Reagent, and Kit for Evaluating Susceptibiity to Same
AU747449B2 (en) Recombinant viruses, preparation and use thereof in gene therapy
Vaessen et al. Gene therapy in disorders of lipoprotein metabolism
MXPA97006569A (es) Virus recombinantes que expresan la lecitina-colesterol aciltransferasa y sus usos en terapia genica
Raper et al. Gene transfer strategies for metabolic diseases
Belalcazar et al. Somatic gene therapy for dyslipidemias
US8496928B2 (en) Method for preventing and treating cardiovascular diseases with BRCA1
MXPA99004301A (es) Adenovirus recombinantes bicistronicos para el tratamiento de patologias relacionadas a las dislipoproteinemias